Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

RAHWAY, N.J.--( BUSINESS WIRE )--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Phase 3 NRG-GY018 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, in combination with standard of care chemotherapy (carboplatin and paclitaxel) met its primary endpoint of progression-free survival (PFS) for the treatment of patients with stage III-IV or recurrent endometrial carcinoma regardless of mismatch repair status. At a pre-specified interim analysis review conducted by an independent Data Monitoring Committee, KEYTRUDA in combination with chemotherapy then continued as single agent every six weeks for up to 14 cycles demonstrated a statistically significant and clinically meaningful improvement in PFS compared with chemotherapy alone in these patients whose endometrial carcinoma was either mismatch repair proficient (pMMR) or mismatch repair deficient (dMMR).

Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma

Amgen

Cisco Systems

Dow Inc

Goldman Sachs

Intel

Verizon

While investing in the new normal seemingly focused on meme trades and other high-risk ventures, targeting the companies of the Dow Jones is always relevant, particularly if they're among the most undervalued Dow stocks to buy. Granted, this venerable list doesn't bring much excitement.

The 7 Most Undervalued Dow Stocks to Buy in February 2023

Merck (MRK) beats Q4 estimates for earnings and sales. Its 2023 profit guidance disappoints.

Merck (MRK) Beats on Q4 Earnings & Sales, 2023 View Disappoints

Merck & Co., Inc. (NYSE:MRK ) Q4 2022 Earnings Conference Call February 2, 2023 8:00 AM ET Company Participants Peter Dannenbaum - Vice President, Investor Relations Rob Davis - Chairman and CEO Caroline Litchfield - Chief Financial Officer Dr.

Merck & Co., Inc. (MRK) Q4 2022 Earnings Call Transcript

Merck & Co Inc (NYSE:MRK) has delivered fourth-quarter revenue and earnings that beat expectations, supported by strong sales of its cancer immunotherapy Keytruda. However, shares of the Rahway, New Jersey-based drugmaker fell in early New York trade after its 2023 outlooked fell short of expectations.

Merck delivers 4Q earnings beat but shares fall on 2023 outlook

Honeywell

Even as the S&P 500 climbed, weaker performance from Dow components held the average back.

Why These 2 Stocks Made the Dow Miss the Market Rally

Merck's profit guidance for 2023 widely missed Wall Street's projections on Thursday, leading Merck stock to crumble despite a quarterly beat. The post Merck Lands In Hot Water After 2023 Profit Guidance Widely Misses Forecasts appeared first on Investor's Business Daily.

Merck Lands In Hot Water After 2023 Profit Guidance Widely Misses Forecasts

Merck (MRK) delivered earnings and revenue surprises of 3.85% and 0.65%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Merck (MRK) Beats Q4 Earnings and Revenue Estimates

Merck stock dipped Thursday after its profit outlook for 2023 widely missed forecasts, though fourth-quarter metrics beat. The post Merck's 2023 Earnings Guidance Widely Missed; Shares Slide appeared first on Investor's Business Daily.

Merck's 2023 Earnings Guidance Widely Missed; Shares Slide

Shares of Merck & Co. Inc. MRK, -0.40% fell 0.9% in premarket trading Thursday, after the drug giant reported fourth-quarter results that beat expectations, but provided a full-year profit outlook that was below forecasts. Net income fell to $3.02 billion, or $1.18 a share, from $3.76 billion, or $1.48 a share, in the year-ago period.

Merck stock falls after quarterly earnings top expectations but profit outlook disappoints

Microsoft

Walmart

Not every company is built to thrive -- or even survive -- for the long haul. These are.

Got $5,000? 3 Stocks to Hold for the Next 20 Years

Merck & Co on Thursday forecast a sharp decline in sales of its COVID-19 antiviral pill as the pandemic eases globally.

Merck forecasts sharp drop in COVID antiviral pill sales in 2023

RAHWAY, N.J.--( BUSINESS WIRE )--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2022.

Merck Announces Fourth-Quarter and Full-Year 2022 Financial Results

Investors will be watching to see how Merck's guidance for its 2023 financial performance lines up with expectations.

Merck Earnings Are Coming. What to Watch For.

Merck's (MRK) key products like cancer drug Keytruda and HPV vaccine Gardasil are expected to have driven sales in Q4.

Will Keytruda & Gardasil Aid Merck (MRK) Sales in Q4 Earnings?

Merck & Co. (MRK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Merck & Co. (MRK) Might Surprise This Earnings Season

AstraZeneca

Medtronic

These healthcare titans are poised for a strong showing in 2023 and beyond.

3 No-Brainer Dividend Stocks to Buy Hand Over Fist in 2023

Pharmaceutical company Merck & Co (NYSE:MRK) is one of the many big names set to announce its quarterly report this week, with earnings scheduled before the open on Thursday, Feb. 2.

Checking in with Merck Stock Before Earnings

Bristol-Myers

ConocoPhillips

Sirius XM Holdings Inc

In late morning trading Tuesday, the Dow Jones industrials were up 0.28%, the S&P 500 up 1.02% and the Nasdaq up 0.66%.

Earnings Previews: Bristol-Myers Squibb, ConocoPhillips, Merck, Sirius XM

Harmony Biosciences Holdings

Eli Lilly

McKesson

Novo Nordisk

UnitedHealth Group

Vir Biotechnology

Healthcare stocks performed well in 2022, driven by a number of factors. One of the main drivers was the ongoing COVID-19 pandemic, which continued to boost demand for healthcare products and services.

7 Healthcare Stocks That Will Be Big Winners in 2023

We expect MRK stock to trade sideways, with its revenue likely falling slightly below and earnings marginally above the street estimates.

Here's What To Expect From Merck's Q4

Merck recently completed its acquisition of a California-based biotech company.

Will This Billion-Dollar Acquisition Be a Smart Move for Merck?

RAHWAY, N.J.--( BUSINESS WIRE )--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck's anti-PD-1 therapy, as a single agent, for adjuvant treatment following surgical resection and platinum-based chemotherapy for adult patients with stage IB (T2a ≥4 centimeters [cm]), II, or IIIA non-small cell lung cancer (NSCLC).

FDA Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment Following Surgical Resection and Platinum-Based Chemotherapy for Patients With Stage IB (T2a ≥4 Centimeters), II, or IIIA Non-Small Cell Lung Cancer (NSCLC)

These two healthcare giants defied the bear market last year.

2 Market-Beating Stocks to Buy in 2023 and Hold for 10 Years

MADISON, N.J.--( BUSINESS WIRE )--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the U.S. Food and Drug Administration's approval of an expanded indication for BRAVECTO® Chews for Dogs. The new indication treats and controls Asian longhorned ticks, which are an invasive Ixodid species located across more than one-third of the U.S1,2.

News for Merck Stock (MRK)